Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: A case report and review of the literature

Shoji Saito, Ryu Yanagisawa, Kentaro Yoshikawa, Yumiko Higuchi, Terutsugu Koya, Kiyoshi Yoshizawa, Miyuki Tanaka, Kazuo Sakashita, Takashi Kobayashi, Takashi Kurata, Koichi Hirabayashi, Yozo Nakazawa, Masaaki Shiohara, Yoshikazu Yonemitsu, Masato Okamoto, Haruo Sugiyama, Kenichi Koike, Shigetaka Shimodaira

Research output: Contribution to journalArticle

25 Citations (Scopus)


A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.

Original languageEnglish
Pages (from-to)330-335
Number of pages6
Issue number3
Publication statusPublished - Mar 1 2015


All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Cite this